newsfilter
← Latest News
GlobeNewswire·

RenovoRx to Host First Quarter 2026 Financial Results and Business Highlights Conference Call on May 14th at 4:30 pm ET

RNXT
  • RenovoRx (NASDAQ: RNXT) will host its first quarter 2026 financial results & business highlights conference call on May 14, 2026, at 4:30 pm ET.
  • Management will highlight commercial momentum including RenovoCath stand-alone device sales in U.S. cancer centers, growth at high-volume institutions, & rising repeat orders.
  • The company will update on the Phase III TIGeR-PaC trial for locally advanced pancreatic cancer, which is nearing full enrollment & targeting first-half 2026 completion with final data expected in 2027.
  • RenovoRx plans to generate new data via post-marketing registry studies & investigator-initiated trials (IITs) in borderline resectable & metastatic pancreatic cancer to expand the TAMP™ platform application.
  • Registry & IIT studies are described as cost-neutral & capital-efficient methods to broaden therapeutic applications.
  • In its first full year of commercial efforts, RenovoRx generated approximately $1.1 million in RenovoCath sales.
  • The company is evaluating the drug-device combination candidate IAG (intra-arterial gemcitabine via RenovoCath) under a U.S. investigational new drug application.
  • IAG received Orphan Drug Designation for pancreatic cancer & bile duct cancer, granting seven years of market exclusivity upon FDA approval.
  • RenovoRx is exploring further revenue-generating activities for the TAMP technology, either independently or through a medical device commercial partner.
  • A live dial-in, webcast, & replay (available until May 28, 2026) will be provided for the conference call via the Investor Relations website.